Ligand id: 7335

Name: nivolumab

1. Callahan MK, Wolchok JD. (2013)
At the bedside: CTLA-4- and PD-1-blocking antibodies in cancer immunotherapy.
J. Leukoc. Biol., 94 (1): 41-53. [PMID:23667165]
2. FDA. 
FDA approves nivolumab plus ipilimumab combination for intermediate or poor-risk advanced renal cell carcinoma.
Accessed on 18/04/2018. Modified on 18/04/2018.,
3. FDA. 
Nivolumab in combination with ipilimumab.
Accessed on 17/06/2016. Modified on 17/06/2016. US Food and Drug Administration,
4. Greaves P, Gribben JG. (2013)
The role of B7 family molecules in hematologic malignancy.
Blood, 121 (5): 734-44. [PMID:23223433]
5. Hall RD, Gray JE, Chiappori AA. (2013)
Beyond the standard of care: a review of novel immunotherapy trials for the treatment of lung cancer.
Cancer Control, 20 (1): 22-31. [PMID:23302904]
6. Hamid O, Carvajal RD. (2013)
Anti-programmed death-1 and anti-programmed death-ligand 1 antibodies in cancer therapy.
Expert Opin Biol Ther, 13 (6): 847-61. [PMID:23421934]
7. Intlekofer AM, Thompson CB. (2013)
At the bench: preclinical rationale for CTLA-4 and PD-1 blockade as cancer immunotherapy.
J. Leukoc. Biol., 94 (1): 25-39. [PMID:23625198]
8. Janakiram M, Abadi YM, Sparano JA, Zang X. (2012)
T cell coinhibition and immunotherapy in human breast cancer.
Discov Med, 14 (77): 229-36. [PMID:23114578]
9. Kline J, Gajewski TF. (2010)
Clinical development of mAbs to block the PD1 pathway as an immunotherapy for cancer.
Curr Opin Investig Drugs, 11 (12): 1354-9. [PMID:21154117]
10. Korman AJ, Srinivasan M, Wang C, Selby MJ, Chen B, Cardarelli JM. (2006)
Human monoclonal antibodies to programmed death 1(pd-1) and methods for treating cancer using anti-pd-1 antibodies alone or in combination with other immunotherapeutics.
Patent number: WO2006121168. Assignee: Ono Pharmaceutical Co. Priority date: 09/05/2005. Publication date: 02/03/2015.
11. Larkin J, Chiarion-Sileni V, Gonzalez R, Grob JJ, Cowey CL, Lao CD, Schadendorf D, Dummer R, Smylie M, Rutkowski P et al.. (2015)
Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma.
N. Engl. J. Med., 373 (1): 23-34. [PMID:26027431]
12. Luke JJ, Ott PA. (2015)
PD-1 pathway inhibitors: the next generation of immunotherapy for advanced melanoma.
Oncotarget, 6 (6): 3479-92. [PMID:25682878]
13. Motzer RJ, Escudier B, McDermott DF, George S, Hammers HJ, Srinivas S, Tykodi SS, Sosman JA, Procopio G, Plimack ER et al.. (2015)
Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma.
N. Engl. J. Med., 373 (19): 1803-13. [PMID:26406148]
14. Motzer RJ, Tannir NM, McDermott DF, Arén Frontera O, Melichar B, Choueiri TK, Plimack ER, Barthélémy P, Porta C, George S et al.. (2018)
Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma.
N. Engl. J. Med., 378 (14): 1277-1290. [PMID:29562145]
15. O'Sullivan Coyne G, Madan RA, Gulley JL. (2014)
Nivolumab: promising survival signal coupled with limited toxicity raises expectations.
J. Clin. Oncol., 32 (10): 986-8. [PMID:24590655]
16. Pardoll DM. (2012)
The blockade of immune checkpoints in cancer immunotherapy.
Nat. Rev. Cancer, 12 (4): 252-64. [PMID:22437870]
17. Postow MA, Chesney J, Pavlick AC, Robert C, Grossmann K, McDermott D, Linette GP, Meyer N, Giguere JK, Agarwala SS et al.. (2015)
Nivolumab and ipilimumab versus ipilimumab in untreated melanoma.
N. Engl. J. Med., 372 (21): 2006-17. [PMID:25891304]
18. Tang PA, Heng DY. (2013)
Programmed death 1 pathway inhibition in metastatic renal cell cancer and prostate cancer.
Curr Oncol Rep, 15 (2): 98-104. [PMID:23263823]
19. Topalian SL, Drake CG, Pardoll DM. (2015)
Immune checkpoint blockade: a common denominator approach to cancer therapy.
Cancer Cell, 27 (4): 450-61. [PMID:25858804]